The GLP-1 receptor agonists, liraglutide and semaglutide, appear to represent a first-line option in obese patients with NAFLD and T2DM since they induce considerable weight loss and have been extensively studied in patients with T2DM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.